To the Editor,A multicenter,open-label,early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma

Abstract

Get full access to this article

View all access options for this article.

References

Stephens

Spurgeon

. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol 2015; 6: 242–252.

National Cancer Institute. Mantle cell lymphoma. Surveillance, Epidemiology, and End Results Program Website, http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5357 (2015, accessed 16 November 2015).

Jares

Colomer

Campo

. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750–762.

Cheah

Chihara

Romaguera

et al.

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 2015; 26: 1175–1179.

Ghielmini

Zucca

. How I treat mantle cell lymphoma. Blood 2009; 114: 1469–1476.

Advani

Buggy

Sharman

et al.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88–94.

Byrd

Furman

Coutre

et al.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.

Honigberg

Smith

Sirisawad

et al.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010; 107: 13075–13080.

Wang

Rule

Martin

et al.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516.

10.

Wang

Blum

Martin

et al.

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126: 739–745.

11.

Pharmacyclics, LLC. Imbruvica (ibrutinib) (prescribing information), Sunnyvale, CA: Pharmacyclics, LLC, 2017.

12.

US Food and Drug Administration. Expanded access to investigational drugs for treatment use—questions and answers. US Food and Drug Administration Website, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm351261.pdf (2016; accessed 26 July 2016).

13.

Patil

. Early access programs: benefits, challenges, and key considerations for successful implementation. Perspect Clin Res 2016; 7: 4–8.

14.

Dreyling

Jurczak

Jerkeman

et al.

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 2016; 387: 770–778.